Amarantus BioScience Holdings, Inc. Stock (AMBS) - Quote OTC Markets- MarketScreener (2024)

Delayed OTC Markets Other stock markets 03:41:25 2024-05-24 pm EDT			5-day change	1st Jan Change
0.0001 ^USD	-.--%		-.--%	-80.00%

2022	Sector Update: Financial Stocks Still Adding to Wednesday Declines	MT
2020	Todos Medical Ltd. (OTCPK:TOMD.F) completed the acquisition of remaining 80.01% stake in Breakthrough Diagnostics Inc. from Amarantus BioScience Holdings, Inc.	CI

Financials (USD)

Sales 2014	-	Sales 2015	-	Capitalization	8.57M
Net income 2014	-27M	Net income 2015	-25M	EV / Sales 2014	-
Net cash position 2014	89K	Net Debt 2015	2.96M	EV / Sales 2015	-
P/E ratio 2014	-2.06x	P/E ratio 2015	-0.15x	Employees	12
Yield 2014 *	-	Yield 2015	-	Free-Float	100%

More Fundamentals * Assessed data

Chart Amarantus BioScience Holdings, Inc.

Duration

Latest news about Amarantus BioScience Holdings, Inc.

Sector Update: Financial Stocks Still Adding to Wednesday Declines	22-03-30	MT
Todos Medical Ltd. (OTCPK:TOMD.F) completed the acquisition of remaining 80.01% stake in Breakthrough Diagnostics Inc. from Amarantus BioScience Holdings, Inc.	20-07-27	CI
Amarantus BioScience Holdings, Inc. acquired majority interest in Hempori, Inc. for $0.38 million.	20-01-29	CI
Amarantus Completes Sublicense of ESS, MANF and Phenoguard to Emerald Organic Products	20-01-02	CI
Amarantus Announces Issuance of Chinese Patent Covering the Use of MANF and CDNF in Retinal Disorders for Subsidiary Manf Therapeutics	19-11-21	CI
Amarantus Bioscience Holdings, Inc. Enters into Agreement to License Diverse Therapeutics Portfolio to CBD-Focused Emerald Organic Products with Emerald Organic Growth, Inc	19-10-24	CI
Coeptis Pharmaceuticals, Inc. terminated the acquisition of Elto Pharma, Inc. from PsychoGenics Inc. and Amarantus BioScience Holdings, Inc..	19-10-23	CI
Amarantus Enters into Letter of Intent with the Alchemists Kitchen to Establish Joint Venture for Research and Commercialization of Hemp and Herbal Smokables for Addiction Treatment Including Smoking Cessation	19-06-25	CI
Amarantus BioScience Holdings, Inc. Announces Positive Pre-Clinical Data for Manf in Wolfram Syndrome	19-06-18	CI
Amarantus Hires Evolution Venture Partners To Evaluate Alternatives For Expansion Into Legal Hemp	19-05-28	CI
Todos Medical Ltd. (OTCPK:TOMD.F) exercised the option to acquire the remaining 80.01% stake in Breakthrough Diagnostics Inc. from Amarantus BioScience Holdings, Inc..	19-04-21	CI
Amarantus Announces Commercialization Partnership With IDEA Pharma for Subsidiaries	19-01-11	CI
Todos Medical Ltd. Enters into Joint Venture Agreement with Amarantus to Develop AlzheimerS Blood Diagnostic Lympro Test 2.0	18-12-03	CI
Coeptis Pharmaceuticals, Inc. entered into a binding agreement to acquire Elto Pharma, Inc. from PsychoGenics Inc. and Amarantus BioScience Holdings, Inc..	18-11-27	CI
Amarantus Enters into Exclusive Option Agreement with Leipzig University to License IP Covering Alzheimer's Blood Diagnostic LymPro Test 2.0 Blood Test Vs. Amyloid Pet	18-05-04	CI

More news

Press releases Amarantus BioScience Holdings, Inc.

Amarantus BioScience : Notification of Late Filing	21-11-18	PU
Amarantus BioScience : Todos Medical Completes Acquisition of Breakthrough Diagnostics, Gains Full Rights to the Alzheimer’s Blood Diagnostic LymPro™ Test from Amarantus	20-07-28	AQ
Emerald Organic Products : Restructures Joint Venture Agreement With Todos Medical by Entering Joint Collaboration Agreement	20-05-08	AQ
Amarantus BioScience : Todos Medical and 3DMed Enter Into Coronavirus (COVID-19) and Influenza A/B Testing Kit Distribution Agreement in US and Israel	20-03-17	AQ
Amarantus BioScience : Announces Subsidiary MANF Therapeutics Enters Into Material Transfer Agreement with Dyadic International	20-02-06	AQ

More press releases

Quotes and Performance

3 months	-50.00%
6 months	-90.00%
Current year	-80.00%

More quotes

Highs and lows

1 month

0.00

Managers and Directors - Amarantus BioScience Holdings, Inc.

Managers	Title	Age	Since
John W. Commissiong FOU	Founder	79	08-01-13
Gerald E. Commissiong FOU	Founder	41	08-01-13
Donald Huffman CEO	Chief Executive Officer	77	14-07-21

Members of the board	Title	Age	Since
Donald Huffman CEO	Chief Executive Officer	77	14-07-21
John W. Commissiong FOU	Founder	79	08-01-13
Gerald E. Commissiong FOU	Founder	41	08-01-13

More insiders

Company Profile

Amarantus Bioscience Holdings, Inc. is a biopharmaceutical company. The Company is focused on developing therapeutic product candidates in the areas of neurology, psychiatry, ophthalmology and regenerative medicine. The Company owns or has licenses to various product candidates in the biopharmaceutical healthcare industry. It has acquired the rights to the engineered skin substitute program (ESS), a regenerative medicine-based approach for treating severe burns with full-thickness autologous skin grown in tissue culture that is being pursued by Companyâs wholly owned subsidiary Cutanogen Corporation. The Companyâs wholly owned subsidiary MANF Therapeutics, Inc. owns intellectual property rights and licenses from a number of prominent universities related to the development of the therapeutic protein known as mesencephalic astrocyte-derived neurotrophic factor (MANF). MANF Therapeutics, Inc. is developing MANF-based products as treatments for ophthalmological disorders.

Sector

More about the company

	1st Jan change	Capi.
AMARANTUS BIOSCIENCE HOLDINGS, INC.	-80.00%	63.04K
MODERNA, INC.	+53.31%	59.28B
LONZA GROUP AG	+41.42%	40.94B
IQVIA HOLDINGS INC.	-5.46%	40.17B
CELLTRION, INC.	-5.16%	28.69B
ICON PUBLIC LIMITED COMPANY	+12.59%	26.63B
ALNYLAM PHARMACEUTICALS, INC.	-20.38%	18.89B
MEDPACE HOLDINGS, INC.	+30.75%	12.46B
BIO-TECHNE CORPORATION	+0.28%	12.42B
UNITED THERAPEUTICS CORPORATION	+26.19%	12.26B

Stock Market
Equities
AMBS Stock

+201.5% on SUPER MICRO COMPUTER since our purchase on February 17, 2023 Replicate our performance

"); InvestingChannelQueue.push(function() { aICTags["oop"] = ic_page.defineOutOfPageTag("4Traders/quotepages","zppOOP"); aICTags["oop"].setKval({"adslot":"d_OOP_1"}); aICTags["oop"].render(); }); while (aAdsQueue.length) { (aAdsQueue.shift())(); } InvestingChannelQueue.push(function() { displayViewableAds('InvestingChannel'); $( window ).scroll(function() { displayViewableAds('InvestingChannel'); }); }); }gaEvent('adspv', 'InvestingChannel', 'US');googletag.cmd.push(function() { googletag.pubads().setTargeting('Edition', 'en_US');googletag.pubads().setTargeting('UserType', 'free');googletag.pubads().setTargeting('Content', 'equities');googletag.pubads().setTargeting('codezb', '120793428');googletag.enableServices();googletag.pubads().collapseEmptyDivs();try{googletag.pubads().getSlots().forEach(function(slot){if(slot.getSlotElementId().startsWith('zpp')){;}else{googletag.pubads().refresh([slot],{changeCorrelator: false});}})}catch(error){console.error(error)}});$(document).ready(function() { $( document).on('zbv_visible',function () {startAdsService();}); if (document[zbv_hidden]===false) { startAdsService(); } });